Docosahexaenoic Acid
Immune System Diseases
University of CatanzaroSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Immune System Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Indapta Therapeutics, INC. | Phase 2 | BB |
Monomethyl Fumarate National Cancer Institute (NCI) | Phase 2 | BB |
Fludarabine Indapta Therapeutics, INC. | Phase 2 | BB |
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 2 | BB |
Zilovertamab Oncternal Therapeutics, Inc | Phase 3 | B |
View all 33 →
Same molecule, other indications
Docosahexaenoic Acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →